Vasantha Thavaraj1, Rachna Seth. 1. Pediatric Oncology Division, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India. sowmyam.vasantha@gmail.com
Abstract
BACKGROUND: Chronic myeloid leukemia (CML) in blast crisis has a dismal prognosis. Imatinib mesylate (IM) is a new drug which has been shown to induce complete hematological remission in 55% and complete cytogenetic response in 22% of the patients with CML in blast crisis. METHODS: A child with CML in lymphoid blast crisis was diagnosed by complete hematological and bone marrow examination. There was no central nervous system (CNS) leukemia at presentation. The child was treated with IM at a daily dose of 400 mg. RESULTS: The child showed remission after IM administration for 28 days and remained in remission till 59 days. On day 59 she experienced headache and vomiting. Results of cerebrospinal fluid taken for cytopathology showed CNS leukemia. MCP 841 protocol for ALL and weekly intrathecal triple therapy (ITT) was given. CONCLUSIONS: Along with IM treatment in patients with CML in blast crisis, weekly ITT with hydrocortisone, cytosine arabinoside and methotrexate should be recommended to prevent CNS involvement.
BACKGROUND:Chronic myeloid leukemia (CML) in blast crisis has a dismal prognosis. Imatinib mesylate (IM) is a new drug which has been shown to induce complete hematological remission in 55% and complete cytogenetic response in 22% of the patients with CML in blast crisis. METHODS: A child with CML in lymphoid blast crisis was diagnosed by complete hematological and bone marrow examination. There was no central nervous system (CNS) leukemia at presentation. The child was treated with IM at a daily dose of 400 mg. RESULTS: The child showed remission after IM administration for 28 days and remained in remission till 59 days. On day 59 she experienced headache and vomiting. Results of cerebrospinal fluid taken for cytopathology showed CNS leukemia. MCP 841 protocol for ALL and weekly intrathecal triple therapy (ITT) was given. CONCLUSIONS: Along with IM treatment in patients with CML in blast crisis, weekly ITT with hydrocortisone, cytosine arabinoside and methotrexate should be recommended to prevent CNS involvement.
Authors: Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra Journal: N Engl J Med Date: 2002-02-28 Impact factor: 91.245
Authors: B J Druker; C L Sawyers; H Kantarjian; D J Resta; S F Reese; J M Ford; R Capdeville; M Talpaz Journal: N Engl J Med Date: 2001-04-05 Impact factor: 91.245
Authors: J D Griffin; R F Todd; J Ritz; L M Nadler; G P Canellos; D Rosenthal; M Gallivan; R P Beveridge; H Weinstein; D Karp; S F Schlossman Journal: Blood Date: 1983-01 Impact factor: 22.113
Authors: A Bakhshi; J Minowada; A Arnold; J Cossman; J P Jensen; J Whang-Peng; T A Waldmann; S J Korsmeyer Journal: N Engl J Med Date: 1983-10-06 Impact factor: 91.245
Authors: Martin A Champagne; Renaud Capdeville; Mark Krailo; Wenchun Qu; Bin Peng; Marianne Rosamilia; Martine Therrien; Ulrike Zoellner; Susan M Blaney; Mark Bernstein Journal: Blood Date: 2004-07-01 Impact factor: 22.113
Authors: Heike Pfeifer; Barbara Wassmann; Wolf-Karsten Hofmann; Martina Komor; Urban Scheuring; Patrick Brück; Anja Binckebanck; Eberhard Schleyer; Nicola Gökbuget; Thomas Wolff; Michael Lübbert; Lothar Leimer; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann Journal: Clin Cancer Res Date: 2003-10-15 Impact factor: 12.531
Authors: Jose F Leis; Daniel E Stepan; Peter T Curtin; John M Ford; Bin Peng; Susan Schubach; Brian J Druker; Richard T Maziarz Journal: Leuk Lymphoma Date: 2004-04